Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Jun. 2025,
DocMorris AG receivedCHF212 Mil more from issuing new shares than it paid to buy back shares.
It receivedCHF0 Mil from issuing more debt.
It paidCHF0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedCHF0 Mil from paying cash dividends to shareholders.
It spentCHF13 Mil on other financial activities.
In all, DocMorris AGearnedCHF199 Mil on financial activities for the
six
months ended in Jun. 2025.
DocMorris AG (XSWX:DOCM) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
DocMorris AG's issuance of stock for the
six
months ended in Jun. 2025 was CHF212 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
DocMorris AG's repurchase of stock for the
six
months ended in Jun. 2025 was CHF0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
DocMorris AG's net issuance of debt for the
six
months ended in Jun. 2025 was CHF0 Mil.
DocMorris AG receivedCHF0 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
DocMorris AG's net issuance of preferred for the
six
months ended in Jun. 2025 was CHF0 Mil.
DocMorris AG paidCHF0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
DocMorris AG's cash flow for dividends for the
six
months ended in Jun. 2025 was CHF0 Mil.
DocMorris AG receivedCHF0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
DocMorris AG's other financing for the
six
months ended in Jun. 2025 was CHF-13 Mil.
DocMorris AG spentCHF13 Mil on other financial activities.
DocMorris AG Cash Flow from Financing Related Terms
DocMorris AG Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for DocMorris AG's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
DocMorris AG's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF104 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of CHF104 Mil mean?
DocMorris AG (XSWX:DOCM) has a Cash Flow from Financing of CHF104 Mil as of Jun. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for DocMorris AG and its competitors.
Is DocMorris AG's Cash Flow from Financing too high?
DocMorris AG's current Cash Flow from Financing is CHF104 Mil. Overall, DocMorris AG has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DocMorris AG's Cash Flow from Financing compare to competitors?
DocMorris AG's Cash Flow from Financing of CHF104 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Healthcare Providers & Services company?
A good Cash Flow from Financing depends on the Healthcare Providers & Services industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for DocMorris AG and its competitors. DocMorris AG's current Cash Flow from Financing is CHF104 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocMorris AG stock overvalued right now?
Based on GuruFocus' analysis, DocMorris AG (XSWX:DOCM) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF10.53, compared to a current price of CHF8.30 — trading 21.2% below its estimated fair value. The current Cash Flow from Financing is CHF104 Mil. DocMorris AG's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For DocMorris AG (XSWX:DOCM), the current Cash Flow from Financing is CHF104 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DocMorris AG (XSWX:DOCM) Overvalued in 2026?
Based on GuruFocus' analysis, DocMorris AG stock appears to be undervalued.
The current stock price of CHF8.30 is trading 21.2% below its estimated GF Value™ of CHF10.53.
GuruFocus considers DocMorris AG to be Modestly Undervalued.
Key valuation signals for XSWX:DOCM:
Cash Flow from Financing: CHF104 Mil
GF Value™: CHF10.53 vs. price of CHF8.30 (21.2% below fair value)
No single metric tells the full story. See the XSWX:DOCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DocMorris AG is engaged in the fields of online pharmacy, marketplace, and professional healthcare with brands in Germany and other European countries. Its brands are DocMorris, PromoFarma by DocMorris, and TeleClinic. The Group's reportable segments are Germany and Europe. The Germany segment comprises the mail-order business in drugs and health products, as well as services for mail-order pharmacies. The Europe segment comprises the marketplace business of PromoFarma and Doctipharma. The majority of revenue is generated from Germany segment.
65GF Score
Get the complete analysis for XSWX:DOCM
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DOCM has been successfully added to your 
